← back to search

Hélène Zéphir

Université Claude Bernard Lyon 1 · FR
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Medicine, Multiple sclerosis, Neuromyelitis optica, Internal medicine, Rituximab, and Expanded Disability Status Scale.
h-index
citations
2,003
works
31
NIH funding
primary concept
email

Recent publications

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT
Nature Reviews Neurology 2025cited by 42position: lastdoi
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
Neurology 2025cited by 8position: middledoi
Brain atrophy patterns in anti-IgLON5 disease
Brain 2025cited by 5position: middledoi
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis
Neurology Neuroimmunology & Neuroinflammation 2025cited by 4position: middledoi
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
JAMA Neurology 2024cited by 44position: middledoi
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
JAMA Neurology 2024cited by 32position: middledoi
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
JAMA Neurology 2024cited by 22position: middledoi
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis
Neurology 2024cited by 5position: middledoi
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Frontiers in Immunology 2023cited by 129position: middledoi
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
Neurology 2023cited by 23position: middledoi
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
Journal of Neuroinflammation 2022cited by 63position: middledoi
Longitudinal Retinal Changes in <scp>MOGAD</scp>
Annals of Neurology 2022cited by 56position: middledoi
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology 2022cited by 46position: middledoi
Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease
Multiple Sclerosis Journal 2022cited by 17position: middledoi
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
Neurology 2022cited by 17position: middledoi
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament‐light chain in multiple sclerosis
Annals of Clinical and Translational Neurology 2021cited by 88position: middledoi
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
JAMA Network Open 2021cited by 84position: middledoi
Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis
Brain Communications 2021cited by 56position: middledoi
A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
Annals of Clinical and Translational Neurology 2021cited by 41position: middledoi
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Annals of Neurology 2020cited by 258position: middledoi
Evaluation of efficacy and tolerability of first-line therapies in NMOSD
Neurology 2020cited by 94position: middledoi
MRI characteristics of MOG-Ab associated disease in adults: An update
Revue Neurologique 2020cited by 26position: middledoi
Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Journal of Neuroinflammation 2019cited by 157position: middledoi
Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study
Multiple Sclerosis Journal 2019cited by 68position: middledoi
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
Journal of Neurology 2019cited by 64position: middledoi
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France
JAMA Neurology 2019cited by 61position: middledoi
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
Neurology 2019cited by 43position: middledoi
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Revue Neurologique 2018cited by 62position: middledoi
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Multiple Sclerosis Journal 2016cited by 112position: middledoi
Aquaporin-4 antibody–negative neuromyelitis optica
Neurology 2013cited by 171position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Romain Marignier · Hospices Civils de Lyon11 papers (2013–2023)Nicolas Collongues · Université Claude Bernard Lyon 110 papers (2013–2023)Sandra Vukusic · Université Claude Bernard Lyon 110 papers (2013–2022)Bertrand Audoin · Université Claude Bernard Lyon 19 papers (2016–2023)Caroline Papeix · Université Claude Bernard Lyon 19 papers (2013–2023)David Laplaud · Université Claude Bernard Lyon 19 papers (2016–2023)Jonathan Ciron · Université Claude Bernard Lyon 18 papers (2018–2023)Bertrand Bourre · Université Claude Bernard Lyon 18 papers (2016–2023)Élisabeth Maillart · Sorbonne Université8 papers (2019–2023)de Sèze · Hôpital d'Hautepierre7 papers (2013–2023) · 6 papers (2019–2023)Mikaël Cohen · Southwestern Medical Center6 papers (2020–2023)Xavier Ayrignac · Université Claude Bernard Lyon 15 papers (2019–2023)Aurélie Ruet · Université Claude Bernard Lyon 15 papers (2020–2023) · 3 papers (2016–2021)Éric Thouvenot · Université de Nîmes3 papers (2019–2023)Françoise Durand‐Dubief · Lyon College3 papers (2019–2023)Romain Casey · Université Claude Bernard Lyon 13 papers (2013–2022)Christine Lebrun‐Frénay · Institut de Recherche sur le Cancer et le Vieillissement de Nice2 papers (2021–2022)Laure Michel · Université Claude Bernard Lyon 12 papers (2022–2023)